Magenta Therapeutics, Inc.
MGTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 105.2% | -83.4% | -81.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | 0% | 0% | 0% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,259.1% | -18,096.9% | -2,852.7% | -576.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,284.1% | -16,388.1% | -2,537.5% | -518.6% |
| EPS Diluted | -9.41 | -8.1 | -7.55 | 13.02 |
| % Growth | -16.2% | -7.3% | -158% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |